Pet product manufacturer Novartis Animal Health has revised the package insert for its popular Capstar flea treatment to clarify which cats and dogs can safely receive the drug.
Novartis notified veterinarians of the changes in a “Dear Doctor” letter earlier this year. It also shared the letter with the Food and Drug Administration’s (FDA) Center for Veterinary Medicine in Rockville, Md., which had recommended the revisions following a routine review of consumer experience with the product.
The new insert states that Capstar oral tablets are for cats and dogs “2 pounds of body weight or greater and 4 weeks of age or older.” The previous version listed the restrictions in reverse order. The change was made because the “2 pounds or greater” direction was seen as the more important restriction, Novartis spokesman Mickey McDermott told joltleft.com. In addition, the wording now appears in bold instead of regular type.
“As growing numbers of animals receive established products such as CAPSTAR tablets (used safely and effectively for over a decade with an estimated 50 million doses distributed), additional information is gleaned and evaluated,” Novartis wrote in the Dear Doctor letter. “Based on this body of knowledge, Novartis Animal Health has made changes to the CAPSTAR package insert,” including “additional guidance to help minimize the risk of future adverse events, such as reinforcing the important message that CAPSTAR tablets are intended for use in dogs and cats that are, at a minimum, 2 pounds in weight and 4 weeks old.”
Click the “SUBSCRIBE” button above to receive e-mail alerts when new cat-health articles are published. Also, follow this cat-health news writer on Twitter.